Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
- 1Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States
- 2Department of Psychology, Yale University, New Haven, CT, United States
- 3Center for Brain and Mind Health, Yale University School of Medicine, New Haven, CT, United States
- 4Child Study Center, Yale University School of Medicine, New Haven, CT, United States
By Ching THW, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk SA, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C and Kelmendi B (2024) Front. Psychiatry. 14:1278823. doi: 10.3389/fpsyt.2023.1278823
Error in Author List
In the published article, there was an error in the author list, and Anastasia Jankovsky was erroneously excluded. The corrected author list appears below.
Terence H. W. Ching,1 Lucia Amoroso,1 Calvin Bohner,1 Elizabeth D'Amico,1 Jeffrey Eilbott,1 Tara Entezar,1 Madison Fitzpatrick,1 Geena Fram,1 Rachael Grazioplene,1 Jamila Hokanson,1 Anastasia Jankovsky,1 Stephen A. Kichuk,1 Bradford Martins,1 Prerana Patel,1 Henry Schaer,1 Sarah Shnayder,1 Chelsea Witherow,1 Christopher Pittenger,1-4 Benjamin Kelmendi1
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: obsessive-compulsive disorder, psilocybin, psychedelic, non-directive support, waitlist, treatment, mental health, adult psychiatry
Citation: Ching THW, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk SA, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C and Kelmendi B (2024) Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Front. Psychiatry 15:1372373. doi: 10.3389/fpsyt.2024.1372373
Received: 17 January 2024; Accepted: 01 February 2024;
Published: 16 February 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Ching, Amoroso, Bohner, D'Amico, Eilbott, Entezar, Fitzpatrick, Fram, Grazioplene, Hokanson, Jankovsky, Kichuk, Martins, Patel, Schaer, Shnayder, Witherow, Pittenger and Kelmendi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Terence H. W. Ching, dGVyZW5jZS5jaGluZ0B5YWxlLmVkdQ==